← Back to directory
SB
SBSara Bailey
Director · Office of National Drug Control Policy
Bailey reported 1 sale and 4 purchases across 5 transactions in the latest tracked 278-T filing.
5trades
1sale
4purchases
Feb. 1, 2026 – March 1, 2026
Last filing: June 11, 2026|Transactions: Feb. 1, 2026 – March 1, 2026
Get Sara Bailey filing alerts
Get an email when Open Cabinet publishes an important update to Sara Bailey's disclosure record.
Confirm via email. No spam, one-click unsubscribe anytime.
Transaction timeline
One mark per disclosed trade, sized by reported amount range. Circle = sale, square = purchase.
Sale
Purchase
Late filing
|
Mark size = reported amount range (minimum)
Filter5 trades
| Date | Description | Type | Amount | Source |
|---|---|---|---|---|
| March 1, 2026 | Byrna Technologies Inc. Common Stock | Purchase | $1K-$15K | |
| March 1, 2026 | Fidelity Advisor Biotechnology Fund Class C Shares | Purchase | $1K-$15K |
Source documents on file with OGE
Reviewed financial disclosure documents the Office of Government Ethics has published or recorded for Sara Bailey. Open Cabinet summarizes listed documents observationally and links to the source PDF where one is publicly available. We do not issue compliance verdicts — that is OGE’s role, not ours.
Document timeline
Nominee 278Ethics AgreementCompliance Cert278-TCert. of Divestiturefaded = Form 201 only
1 document listed1 publicly downloadable
Source filings
Original PDFs from the U.S. Office of Government Ethics. These are the documents Open Cabinet parses.
Source: U.S. Office of Government Ethics, 278-T Periodic Transaction Report. Asset values and transaction amounts are reported in ranges as required by federal law. View original filings